7 reasons not to wait to treat your hearing loss

2018-03-12T09:01:01

(BPT) – Hearing loss is often referred to as a silent disease. It doesn’t hurt and it often occurs so gradually over time that you barely notice the insidious damage it does. As a result, hard-of-hearing people often delay seeking treatment for their hearing loss.

Here are seven reasons you shouldn’t make that mistake.

1. Hearing loss can be a sign of a more serious illness

While in most cases hearing loss is a result of aging and excessive noise exposure, it can also be a symptom of a serious underlying medical condition. Some of these include tumors, cardiovascular disorders and diabetes. As such, hearing loss should never be dismissed.

2. Untreated hearing loss hurts your career and earning potential

Thinking about hiding your hearing loss at work because it makes you look incompetent and old? Think again! Misunderstanding instructions and asking people to repeat themselves all the time makes others question your ability to do your job. Minimizing communication breakdowns at work by wearing hearing aids will ensure that hearing loss doesn’t become a roadblock for your career.

3. Untreated hearing loss hurts your relationships with loved ones

Did your hearing loss cause you to miss out on a private joke with your pals? Or did you inadvertently hurt your grandchild’s feelings because you didn’t hear them calling you? Since good communication is vital to any close relationship, hearing loss can be hardest on the ones we love the most. Left unresolved, mounting resentment and frustration eventually strains your most cherished relationships.

4. Untreated hearing loss leads to rise in fall risk

Did you know that (along with vision) good hearing also helps you maintain spatial orientation and balance? This is why research has shown that those with even a mild untreated hearing loss are nearly three times more likely to have a history of falling than people with good hearing.

5. Untreated hearing loss has been linked to increased risk for cognitive decline and dementia

There is a growing body of evidence linking untreated hearing loss to physical changes in the brain, accelerated rate of cognitive decline, and cognitive disorders like dementia and Alzheimer’s disease. On the other hand, at least one long-term study shows wearing hearing aids reduces cognitive decline. Why would you take chances?

6. Untreated hearing loss can cause social isolation and depression

When you have a hard time hearing, social activities with friends and family start to become more embarrassing than fun. Your natural recourse may be slowly withdrawing from these activities that you once enjoyed. No wonder, then, that untreated hearing loss frequently leads to social isolation and even depression.

7. Treating hearing loss is easy and painless

Given all these reasons why untreated hearing loss is bad, here’s one piece of good news: Getting treated for hearing loss is easy! Unlike other serious medical conditions that may require surgeries or painful treatments, having your hearing loss evaluated and treated with hearing aids is easy and painless. In fact, most people who finally start to wear hearing aids regret that they didn’t seek treatment earlier.


The best nutrition for your backyard chickens

2018-03-12T15:19:01

(BPT) – Raising backyard chickens has been a growing trend in the United States over the past several years. Consumers crave choice in their family’s diet, which often includes food they have grown or raised themselves. Raising a backyard flock helps consumers have more control over the eggs their family eats, but bringing home chicks for a backyard flock is just the beginning.

The happiest backyard chickens have the healthiest diets, and the best eggs come from hens eating the most nutritious feed. Today, we are increasingly focused on the impact food has on our family’s health. Hobbyists like to feed their flock the way they feed themselves: non-GMO, organic, soy-free, omega-free and all natural.

Having a say in what goes into the food their family eats is one of the main reasons people choose to raise backyard chickens. There are 2.9 million households in the U.S. raising chickens, and 62 percent of backyard hobbyists anticipate adding to their flock in the next three years. Raising chickens is a way to extend food supply, and hobbyists don’t plan to scale back.

Providing healthy food for your family begins with the source. Nutrena poultry feed makes it easy by using wholesome ingredients in its selection of affordable, homegrown, healthy poultry feeds. By providing your chickens with the highest-quality nutrition, you’re sure to have the freshest eggs for that Sunday morning family breakfast.

With companies like Whole Foods Market reporting 426 percent growth in non-GMO sales from 2010 to 2014, it’s evident that consumers want to know what they’re eating. That’s why Nutrena also offers a USDA-certified organic line of poultry feed that is non-GMO.

The Nutrena poultry feed portfolio includes three different feed lines for each type of poultry hobbyist. Whether you’re starting your chicks, supporting your layers or raising meat birds, Nutrena poultry feed offers the nutrition they need.

For more information about the full line of Nutrena feed, visit NutrenaWorld.com.


Kidney disease is more common than you think

2018-03-13T08:01:00

(BPT) – Suffering from high blood pressure and diabetes, Gloria Stephens became extremely bloated and could barely walk, so she knew something else was wrong. She soon learned that her kidneys were failing, and she joined the ranks of the 1 in 7 people with kidney disease. Often called a “silent killer,” kidney disease can cause a person to lose up to 90 percent of kidney function and not even know it.

For National Kidney Month this March, Fresenius Kidney Care — a leading dialysis provider with more than 2,400 centers nationwide caring for more than 190,000 people — urges people to understand the symptoms of kidney disease and what to do if you suspect you may be at risk.

“I tell all of my friends and anyone I meet — you’ve got to ask questions,” recommends Gloria, 69, of Jacksonville, Florida, who now goes to a Fresenius Kidney Care center to receive her life-saving dialysis, which filters her blood because her kidneys no longer function effectively. “You’ve got to know what’s going on in your body.”

Here’s what you should keep in mind to protect yourself from kidney disease:

1. Know Your Risk. As Gloria learned, the two leading causes of kidney disease are high blood pressure and diabetes. Other risk factors include family history of kidney failure, kidney stones, smoking, obesity and cardiovascular disease. Your age — especially if you are over 50 — overall health and even ethnicity can also put you at greater risk for kidney disease. If you are African American, Hispanic or Native American, you may be more prone to the risk factors that lead to kidney disease.

2. Recognize the Symptoms. Signs and symptoms of kidney disease often occur after the condition has progressed, so early detection is key to maintaining kidney health. Talk to your doctor immediately if you notice any changes in your urine, or if you’re experiencing fatigue, itching, swelling in your hands or feet, shortness of breath or pain in the small of your back. Make sure your loved ones are aware of the symptoms, too, because they may notice something you don’t.

3. Get Screened Regularly. If you are at risk for kidney disease, you should be screened by your doctor at least once a year, including blood and urine tests like glomerular filtration rate (GFR). Your estimated GFR (eGFR) is calculated using blood as well as taking into consideration age, weight, body size and gender. The earlier kidney disease is detected, the greater the benefit of treatment.

4. Focus on What Matters Most. While there are many reasons to get healthy, you should focus on what’s important to you, whether it’s spending time with family and friends or doing an activity you love. You’re more likely to stick with a care plan if you have a goal.

“There are a number of things you can easily do to get healthier and decrease your risk of kidney disease, starting with regular testing,” says Dr. Jeffrey Hymes, chief medical officer at Fresenius Kidney Care.

After Gloria was diagnosed with kidney disease, she didn’t expect to walk, drive or live alone again. But she draws strength from her family, stays active and is able to do all of those things. “I get myself to do something every day. If you don’t let negative things turn you around, you’ll be successful,” said Gloria, who is active in her sorority and church and volunteers with children. “The person who I think gives me the greatest amount of encouragement is my little 7-year-old grandniece named Kendall. It’s wonderful when you have a little person in your heart and in your life to keep you going.”

“Patients like Gloria show that focusing on what you love is a powerful factor in coping with kidney disease,” says Dr. Hymes. “Kidney patients and their care teams should address both the physical and emotional aspects of their health and focus on their ‘why’ as part of their treatment plan.”

Learn more about kidney disease by visiting www.freseniuskidneycare.com.


There is an Extended-Release ADHD Treatment Option Available

2018-03-13T16:01:00

(BPT) – An estimated 4.4 percent of adults have Attention Deficit Hyperactivity Disorder (ADHD) in the U.S. — which means that when applied to the full U.S. adult population aged 18 and over, approximately 10.5 million adults are estimated to have ADHD. Medication is not appropriate for all individuals diagnosed with ADHD. ADHD is a neurodevelopmental disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. Many of these adults struggle with symptom management as they go through their day.

On June 20, 2017, the U.S. Food and Drug Administration (FDA) approved MYDAYIS® (mixed salts of a single-entity amphetamine product), an extended-release treatment for ADHD in patients 13 years and older. Mydayis is not for use in children 12 years and younger. In clinical studies, Mydayis demonstrated improved attention up to 16 hours after dosing, beginning at 2 to 4 hours, compared to placebo. Attention was measured using the Permanent Product Measure of Performances (PERMP), a skill-adjusted math test that measures attention in ADHD. Mydayis is now available for appropriate patients by prescription.

Mydayis, other amphetamine containing medicines, and methylphenidate have a high chance for abuse and can cause physical and psychological dependence. Your healthcare provider should check you or your child for signs of abuse and dependence before and during treatment with Mydayis. Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.

Mydayis is a federally controlled substance (CII) because it contains amphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep Mydayis in a safe place to protect it from theft. Never give Mydayis to anyone else, because it may cause death or harm them. Selling or giving away Mydayis may harm others and is against the law.

“The recognition and treatment of ADHD have gone through significant developments in the past 20 years as we’ve come to understand more about how symptoms may impact a patient’s day,” said Dr. Theresa Cerulli, Clinical Instructor at Harvard Medical School. “The availability of multiple, different ADHD treatments, including Mydayis, provides healthcare professionals with different tools they can consider using as part of their patients’ management plans.”

As the understanding of ADHD and the ways it impacts people continues to evolve, it is also important for healthcare professionals to have a range of treatment options to help address the needs of their individual patients. Mydayis provides healthcare professionals with another option for their appropriate patients who may seek an extended-release treatment that helps address their individual needs. People living with ADHD should work with a healthcare professional to determine whether a pharmacological treatment is appropriate for them, and if so, which one helps meet their individual needs.

For more information about Mydayis, talk to your healthcare provider and visit www.MYDAYIS.com.

What is MYDAYIS®?

Mydayis is a prescription medicine for ADHD in patients 13 years and older. Mydayis is not for children 12 years and younger.

IMPORTANT SAFETY INFORMATION

Abuse and dependence. Mydayis, other amphetamine containing medicines, and methylphenidate have a high chance for abuse and can cause physical and psychological dependence. Your healthcare provider should check you or your child for signs of abuse and dependence before and during treatment with Mydayis.

Tell your healthcare provider (HCP) if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Your HCP can tell you how physical and psychological dependence and drug addiction are different.

Mydayis is a federally controlled substance (CII) because it contains amphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep Mydayis in a safe place to protect it from theft. Never give Mydayis to anyone else, because it may cause death or harm them. Selling or giving away Mydayis may harm others and is against the law.

Who should not take Mydayis?

Do not take Mydayis if you or your child is:

  • allergic to amphetamine or any of the ingredients in Mydayis. See Medication Guide for a list of ingredients.
  • taking or have taken a medicine for depression (monoamine oxidase inhibitor [MAOI]) within the past 14 days.

Serious problems can occur while taking Mydayis. Tell your HCP:

  • if you or your child have heart problems, heart defects, high blood pressure, or a family history of these problems. Sudden death has occurred in people with heart problems or defects taking stimulant medicines. Sudden death, stroke and heart attack have happened in adults taking stimulant medicines. Your HCP should check you or your child carefully for heart problems before starting Mydayis. Since increases in blood pressure and heart rate may occur, your HCP should regularly check these during treatment. Call your HCP or go to the ER right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Mydayis.
  • if you or your child have mental (psychiatric) problems, or a family history of suicide, bipolar illness, or depression. New or worse behavior and thought problems or new or worse bipolar illness may occur. New psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms may occur. Call your HCP right away if you or your child have any new or worsening mental symptoms or problems during treatment, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.
  • if your child is having slowing of growth (height or weight). The HCP should check your child’s height and weight often while on Mydayis, and may stop treatment if a problem is found. Mydayis is not for children 12 years and younger.
  • if you or your child have circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon). Fingers or toes may feel numb, cool, painful, sensitive to temperature and/or change color. Call your HCP if you or your child have any of these symptoms or any signs of unexplained wounds appearing on fingers or toes while taking Mydayis.
  • if you or your child have a seizure. Your HCP will stop treatment.
  • if you or your child have symptoms of serotonin syndrome: agitation, hallucinations, coma, or changes in mental status; problems controlling movements or muscle twitching, stiffness, or tightness; fast heartbeat; sweating or fever; nausea, vomiting or diarrhea. Call your HCP or go to the ER if symptoms occur. Serotonin syndrome may occur if Mydayis is taken with certain medicines and may be life-threatening.
  • if you or your child are or become pregnant or plan to become pregnant. It is not known if Mydayis may harm your unborn baby.
  • if you or your child are breastfeeding or plan to breastfeed. You should not breastfeed while taking Mydayis. Mydayis passes into breast milk.

What should I avoid during Mydayis treatment?

  • Avoid drinking alcohol during treatment with Mydayis.

What are possible side effects of Mydayis?

The most common side effects of Mydayis include:

  • trouble sleeping
  • decreased appetite
  • dry mouth
  • increased heart rate
  • anxiety
  • nausea
  • irritability
  • weight loss

For additional safety information, click for Medication Guide and discuss with your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Mydayis is a registered trademark of Shire LLC.

S33443 01/18


Living a Rare Life: Could Your Family History Unlock the Mystery of a Rare, Life-Threatening Condition?

2018-03-13T16:07:01

(BPT) – Imagine your family carried the gene for a rare, life-threatening condition, but didn’t know it?

For generations, members of Angel’s family experienced fatigue, nerve pain, numbness in limbs, dizziness, shortness of breath and chest pain, but were unable to determine the cause. The answer was hereditary ATTR (hATTR) amyloidosis, a progressive, debilitating, life-threatening condition that typically runs in families.

“Early on, my family used to call hATTR amyloidosis ‘the curse’ because no one knew what it was and those who had it experienced a wide variety of symptoms and misdiagnoses,” Angel said. She witnessed firsthand how the condition, which affects approximately 50,000 people worldwide, can devastate a person’s quality of life.

“I watched my grandfather go from building houses and doing construction to being wheelchair bound and bedridden.”

Angel’s family’s experience was recently chronicled in “Living a Rare Life,” a new downloadable booklet sharing their personal account about how they’ve been living with this condition across generations. Like many rare conditions, hATTR amyloidosis varies from individual to individual and is often misdiagnosed because its wide array of symptoms, like shortness of breath, numbness of fingers and toes, constipation/diarrhea and headaches, resemble other, more common conditions.

While the degree and severity of symptoms vary from person to person, hATTR amyloidosis can lead to significant disability and a shortened life expectancy. Obtaining an early and accurate diagnosis is critical.

While Angel tested negative for the condition, she has taken an active role serving as an advocate and caregiver for her family. “The first step to managing a hereditary condition is knowing your family health history and identifying gaps in knowledge about genetic disorders,” said Angel. “Today my mom and many of her siblings are battling hATTR amyloidosis, but now we know how to recognize the symptoms and better manage them.”

Here are a few of Angel’s tips to begin conversations with your loved ones about your health history:

  1. Initiate a Dialogue. Having open and honest conversations about family health history may play a role in identifying symptoms sooner, reaching an accurate diagnosis sooner and allowing your loved ones to take control of their health.
  2. Speak to a Genetic Counselor. Genetic counseling can help your family members understand their chances of inheriting a rare disease gene mutation and become familiar with the testing process. A counselor can help your family to understand potential issues related to genetic testing, like insurance, determine if genetic testing is appropriate and help make sense of results once they are obtained.
  3. Become an Advocate. As an advocate, you can be your family’s most valuable resource for learning about a genetic condition. For some family members, it may be helpful for them to know that they have support throughout the journey of the condition. Building a support system can help the entire family continue to make educated decisions.

If you, or someone in your family, experience symptoms consistent with those of hATTR amyloidosis, talk to your doctor and visit hATTRBridge.com for information and resources like the “Living a Rare Life” booklet.

* Angel is partnering with Alnylam Pharmaceuticals to increase awareness of hATTR amyloidosis.


Couple Inspires Others with Progressive Forms of Multiple Sclerosis (MS)

2018-03-14T11:31:01

(BPT) – More than 20 years ago, as Jennifer Digmann focused on completing her coursework and graduating from college, she began experiencing numbness in her hands and feet and eventually double vision.

After several visits to her primary care doctor, an ophthalmologist and finally a neurologist, she received the diagnosis: multiple sclerosis (MS).

Today, Jennifer lives with a progressive form of MS, a chronic disease that often strikes in the prime of life, has no cure and is the leading cause of non-traumatic disability in young adults. Progressive forms of MS are the most debilitating. Like others who are affected, Jennifer’s symptoms have continued to worsen over time and her level of disability has increased.

Approximately 400,000 people in the U.S. are living with MS, according to the Multiple Sclerosis Association of America. Up to 15 percent are diagnosed with a progressive form of the disease (called Primary Progressive MS), and the majority of those diagnosed with Relapsing MS will transition to a progressive form later in life, according to the National Multiple Sclerosis Society.

For Jennifer, handling her sadness and fear and accepting her diagnosis was almost as challenging as her symptoms. People living with progressive forms of MS tend to experience more difficulties with walking and remaining in the workforce, and they require more assistance with everyday activities, according to the National Multiple Sclerosis Society.

Progressive forms of MS remain frustratingly difficult to treat, primarily because doctors do not fully understand why the disease progresses. Also, many clinical trials for new medicines have been unsuccessful. More research is needed to better understand the underlying biology driving this condition, as well as to develop additional treatment options.

On March 28, 2018, the first ever Progressive MS Day was celebrated by several MS advocacy groups and state governments around the country. This annual day of awareness was created with the goal of recognizing people living with progressive forms of MS, offering support, highlighting resources, programs and services, and, most importantly, calling for further research to advance their care and reduce disability.

Jennifer and her husband, Dan, who himself lives with Relapsing MS, count themselves among the most enthusiastic supporters of Progressive MS Day. As a couple, the Digmanns have dedicated their lives to inspiring and helping others living with MS by sharing their own experiences and perspectives through their blog and radio show.

“My life is not perfect always, but it’s pretty darn good. This disease, my multiple sclerosis, doesn’t hold me back,” says Jennifer.

Seeing the challenges that Jennifer faces with her condition made Dan excited about Progressive MS Day. “Finally, there’s something for people with the progressive forms of MS. Now, hopefully, that opens the door for more awareness and resources, and that’s why a day like this is pivotal,” says Dan.


Chronic anemia: It’s more than meets the eye

2018-03-14T14:17:00

(BPT) – One in every four people is affected by anemia, a condition that occurs when the body lacks enough healthy red blood cells.1,2 Red blood cells carry hemoglobin, a protein that transports oxygen throughout the body, ensuring the body has energy and can function properly.3 Symptoms may vary in severity and can be acute or chronic. Further, many patients present with chronic anemia as a result of other health conditions — cancer, autoimmune and inflammatory diseases, or blood or bone marrow disorders — which each come with their own challenges.2,4,5 For those with chronic anemia associated with other diseases, life after diagnosis often means adjusting to a new “normal.” Dizziness, trouble breathing and overall tiredness experienced by many with anemia may mean adjusting work schedules, changing exercise regimens, limiting social activities and generally slowing down.2

Kathleen Weis, chief executive officer of The Aplastic Anemia and MDS Awareness International Foundation, calls it the “elephant in the room.”6

“Chronic anemia impacts a person’s daily activities. For many, it means not being able to do the things they used to — like going to work or helping around the house. Symptoms, fatigue in particular, can be debilitating,” Weis explained.6

For patients, this may necessitate relinquishing aspects of independence. An increasing reliance on caregivers is one of the hardest transitions people living with chronic anemia face. It’s an entirely new learning process and is often coupled with the guilt of knowing there’s an added burden on family members and caregivers. Patients may even experience depression at one point or another.7

“It’s a double whammy in terms of emotions. Both patients and caregivers are learning how to deal with the changes,” Weis said. “We put a lot of focus on mindfulness and positivity to help patients and their families through these challenges, in addition to educating about treatment. We believe in treating the body and mind together.”6

This March marks the first ever Aplastic Anemia and MDS Awareness Month, an extension from the weeklong observance The Aplastic Anemia and MDS Awareness International Foundation has organized in previous years. Webinars and conferences throughout the month will offer learning opportunities on a wide variety of topics for patients, caregivers and healthcare providers.

Research is another core focus for the Foundation. Treatment options for patients with chronic anemia are limited, and the organization is trying to make sure researching new approaches is seen as a priority. One of the most common treatments is red blood cell transfusions; a process by which donated blood is infused into a patient’s bloodstream.2 Frequency of transfusions depends on disease severity, but some patients may need to be transfused as often as every two weeks.2,8 This is challenging as transfusions are cumbersome, costly and associated with risks.

“Frequent blood transfusions require numerous visits to the doctors, which can be inconvenient for both patients and their caregivers. We would like to see new treatments that not only improve patient outcomes, but may also address current burdens,” said Weis.6

Despite the challenges they face, Weis notes that the patients she meets are resilient. “They want you to know they are still very much moving forward and this thing — this disease — is just something they are dealing with each day.”6

For more information about The Aplastic Anemia and MDS Awareness International Foundation or Aplastic Anemia and MDS Awareness Month, visit http://www.aamds.org/.

REFERENCES:

  1. Pasricha, SR. Anemia: A Comprehensive Global Estimate. Blood. 2014;123(5).
  2. American Cancer Society. Anemia in People With Cancer. Available at https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/anemia.html. Accessed March 2018.
  3. American Cancer Society. Blood Transfusions for People with Cancer. Available at https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/blood-transfusion-and-donation/what-are-transfusions.html. Accessed March 2018.
  4. Smith, Jr., R,E. The Clinical and Economic Burden of Anemia. Am J Manag Care. 2010; 16:S59-S66.
  5. Gunnar Birgegård. Managing Anemia in Lymphoma and Multiple Myeloma. Therapeutics and Clinical Risk Management. 2008;4(2):527–539.
  6. Interview with Kathleen Weis. Conducted by Marissa Vitha and Danielle Kroft for the Celgene Newsroom, January 2018.
  7. Korkmaz S, Yildiz, S, et al. Frequency of anemia in chronic psychiatry patients. Neuropsychiatr Dis Treat. 2015;11:2737–2741. doi: 10.2147/NDT.S91581.
  8. Langhi, Jr., D., et.al. Guidelines on Beta-thalassemia major – regular blood transfusion therapy: Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associac¸ão Médica Brasileira – 2016. Brazilian Journal of Hematology and Hemotherapy. 2016;3:8(4):341–345.


Results are clear: BPA is safe

2018-03-14T16:09:00

For more than 10 years, U.S. government scientists have been conducting an in-depth research program with the goal of answering key scientific questions and resolving remaining uncertainties about the safety of BPA.
This research so far has shown: that human exposure to BPA is low, that people quickly eliminate BPA from their bodies after exposure and that BPA is unlikely to cause health effects at the low levels to which we’re exposed.
If that’s not enough already, the U.S. National Toxicology Program (NTP) released the results of the capstone study of the full research program, known as the CLARITY Core study. It’s the largest study ever conducted on BPA, and the results indicate that BPA has little potential to cause health effects even when people are exposed to it throughout their lives.
In a statement released in conjunction with the report, Dr. Steven Ostroff, Deputy Commissioner for Foods and Veterinary Medicine at the U.S. Food and Drug Administration (FDA) noted: “… our initial review supports our determination that currently authorized uses of BPA continue to be safe for consumers.”
In the study, laboratory animals were exposed to a range of BPA doses from pregnancy, through early-life development and continuing through their entire lifetime. As stated in the conclusion of the study report, BPA produced minimal effects that were distinguishable from background.”
The study was conducted by scientists with FDA’s National Center for Toxicological Research with funding from NTP as part of the CLARITY program (Consortium Linking Academic and Regulatory Insights on BPA Toxicity). The report was issued in draft form and will next undergo peer-review by a panel of experts organized by NTP. The report will then be finalized and the results are expected to be published in the scientific literature.
Based on the body of U.S. government research already available, the consensus of government bodies around the world is that BPA is safe as currently used. Now with the results of the CLARITY core study, the results validate the FDA’s response to the question Is BPA safe? – Yes.